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September 2009702 AbstractsSummary: Studies have shown there are financial benefits in reduc-
ing no-show rates in the clinical setting (J Am Board Fam Pract 2001;
14:193-6; JAMA 1992;267:1813-7). Telephone and mail reminders may
be useful for improving compliance with appointments in the physician’s
office. The effect of no-shows on the noninvasive vascular laboratory has
not been adequately studied. In addition, methods of improving no-
show rates have not been assessed for the vascular laboratory. In this
retrospective study, the authors thought to examine the financial and
scheduling effect of no-shows on the vascular laboratory. They also
reviewed methods to improve patient compliance as well as the literature
on “overbooking” to suggest techniques for reducing rates by extrapo-
lation from nonhealth care industries. They calculate the financial impact
of missed appointments by outpatients during a 9-month period. The
calculation was based on the weighted averaged reimbursement rates for
the technical component of a bilateral venous duplex examination. They
also studied the effect of an automated telephone reminder system on the
no-show rate during a subsequent 17-month period.
The overall no-show rate in the author’s vascular laboratory was 12%.
This was an average of 7.6 missed appointments per week in the outpatient
laboratory. Using the method of calculating financial effects noted above,
this translated into a gross revenue loss of approximately $89,000. There
were 8766 patients offered automated reminder calls, and 4648 (53%)
agreed to receive the call. However, the no-show rate was actually greater for
those patients who chose to receive automated reminder calls than those
who declined such a call (8.9% vs 5.9%, P  .0001).
Comment: Missed appointments are a ubiquitous problem and are
common to many industries other than health care. No-shows in the clinical
setting and in outpatient facilities represent lost revenue opportunities and
create inefficiencies from idle time and increased wait times for new appoint-
ments. This article confirms the adverse financial effect of no-shows on the
vascular laboratory’s bottom line. The discussion accompanying this article
is excellent and indicates particular strategies of overbookingmay be a partial
solution to the no-show problem in outpatient vascular laboratories but may
not be useful in laboratories that also serve a large inpatient population. The
primary limitation to this study is that it does not address the root causes of
patient no-shows. As the squeeze on health care dollars continues to tighten,
physicians will need to examine all aspects of their business and how to make
it more efficient.
Randomized Clinical Trial of Concomitant or Sequential Phlebectomy
After Endovenous Laser Therapy for Varicose Veins
Carradice D, Mekako AI, Hatfield J, et al. Brit J Surg 2009;96:369-75.Conclusions: Phlebectomy performed in conjunction with endovenous
laser therapy (EVLT) increases the length of the index procedure but reduces
the need for secondary procedures and improves quality of life and venous
symptoms.
Summary: It has been suggested that branch varicosities of the great
saphenous vein (GSV) can be left untreated at the time of GSV EVLT
because many patients after EVLT will not require or opt for subsequent
phlebectomy. Others advocate concomitant phlebectomy at the time of
EVLT, arguing that this reduces the need for secondary procedures. In this
study, the authors performed a randomized trial to evaluate and compare
ambulatory phlebectomy performed concomitantly with EVLT to the per-
formance of EVLT with late ambulatory phlebectomy as needed.
There were 50 patients with GSV distribution varicose veins ran-
domized to EVLT alone or EVLT with concomitant ambulatory phle-
bectomies (EVLTAP). Procedures were analyzed for procedure duration
and associated pain score. Requirements for secondary procedures and
quality of life after 3 months were analyzed. Quality of life was assessed
with Short Form 36 (SF-36) and EuroQol 5D scores and venous symp-
toms with the Venous Clinical Severity Score and the Aberdeen Varicose
Vein Questionnaire.
The EVLTAP procedures took longer but decreased the performance
of subsequent interventions. EVLTAP did not result in an increase in
immediate postprocedural pain or differences in SF-36 or EuroQol 5D
scores. The Venous Clinical Severity Score was lower at 3 months for
EVLTAP than EVLT alone (0 [range, 0-1] vs 2 [range, 0-2]; P  .001).
There were lower Aberdeen Varicose Vein Questionnaire scores at 6 weeks
(7.9 [range, 4.1-10.7] vs 13.5 [range, 10.9-18.1]; P  .001) in the
EVLTAP vs EVLT-only patients. Aberdeen Varicose Vein Questionnaire
scores were also lower at 3 months in the EVLTAP vs EVLT patients (2.0
[range, 0.4-7.7] vs 9.6 [range, 2.2-13.8]); P  .015). At 1-year after the
procedure, there were no differences in Venous Clinical Severity Scores or
Aberdeen Varicose VeinQuestionnaire scores in the EVLTAP vs EVLT-only
patients.
Comment: The article is severely limited by the small number of
patients in the study. There are too few patients to perform meaningful
analysis of clinically significant subgroups. A larger study stratifying patients
according to the size and number of their branch varicosities is needed.
Patients with only a few small branch varicosities are probably better off
without phlebectomy at the time of GSV ablation. However, patients with
larger branched varicosities or multiple branch varicosities may be best
treated with a concomitant procedure. Until trials with larger numbers are
available, physicians will still have to use individual judgment to determine
which patients with branch varicosities should be treated with selective late,
or routine concomitant, phlebectomy.
